Arif G. Khan

Health Market Quality Research Stream, Level 3, 55 Harrington Street, 
Sydney, NSW, AU 
Health Market Quality Research Stream, Level 3, 55 Harrington Street, 
Sydney, NSW, AU 

Overview

Arif Khan practices practicing medicine in Sydney, Australia.

His clinical expertise encompasses Generalized Anxiety Disorder (GAD), Major Depression, Bipolar Disorder (BPD), and Attention Deficit Hyperactivity Disorder (ADHD).

He is actively involved in clinical research, co-authoring 57 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Health Market Quality Research Stream, Level 3, 55 Harrington Street, Sydney, NSW, Australia
Other Locations
1951 152nd Pl. NE Suite #200, Bellevue, WA 98007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2025
Intervention Type: Drug
Study Drug: SPN-812
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Enrollment Status: Terminated
Publish Date: March 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: August 14, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Enrollment Status: Completed
Publish Date: July 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

57 Total Publications

Bupropion-Dextromethorphan Is a Potential Treatment Combination for Clinically Challenging Apathy.
Bupropion-Dextromethorphan Is a Potential Treatment Combination for Clinically Challenging Apathy.
Journal: The primary care companion for CNS disorders
Published: April 10, 2026

Frequently Asked Questions about Arif G. Khan

Is Arif G. Khan a top-rated expert for Generalized Anxiety Disorder (GAD)?

MediFind is an objective health platform that identifies experts based on real-world data. Arif G. Khan is classified as an Experienced expert for Generalized Anxiety Disorder (GAD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Arif G. Khan participate in research or clinical trials?

Yes. Arif G. Khan has published 57 articles and abstracts on conditions like Generalized Anxiety Disorder (GAD). You can view a list of Arif G. Khan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Khan's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile